Narendranath Epperla, MD, MS

Trials

Studies that name Narendranath Epperla, MD, MS as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 09:51 UTC. Open this list on ClinicalTrials.gov

• Ph1
  NCT07049432 · N-803 Maintenance Therapy Post CAR T-cell Therapy in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas

  University of Utah · withdrawn · B-cell Non Hodgkin Lymphoma · principal investigator
• Ph1
  NCT06824701 · Tazemetostat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

  University of Utah · active not recruiting · Relapsed or Refractory B-cell Non-Hodgkin Lymphoma · principal investigator
• Ph2
  NCT06788964 · Loncastuximab Tesirine and Rituximab as Bridging Therapy Before Standard-of-care CAR-T Therapy in Patients With Large B-cell Lymphoma (CORAL)

  University of Utah · recruiting · Relapsed or Refractory Large B-cell Lymphoma · principal investigator
• Ph1
  NCT06607549 · Loncastuximab Tesirine and Rituximab Following Stereotactic Radiosurgery in Patients With Central Nervous System Lymphomas (SOLAR)

  University of Utah · recruiting · Central Nervous System Lymphoma · principal investigator
• Ph2
  NCT06300528 · Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas

  University of Utah · active not recruiting · Relapsed or Refractory B-cell Non-Hodgkin Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 09:51 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.